Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.18
+0.24 (2.01%)
At close: Dec 5, 2025, 4:00 PM EST
11.94
-0.24 (-1.97%)
After-hours: Dec 5, 2025, 7:51 PM EST
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Amneal Pharmaceuticals stock ranges from a low of $11 to a high of $14. The average analyst price target of $12.67 forecasts a 4.02% increase in the stock price over the next year.
Price Target: $12.67 (+4.02%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 31, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +6.73% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +14.94% | Sep 16, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | -9.69% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | -1.48% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | -9.69% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
3.07B
from 2.79B
Increased by 9.99%
Revenue Next Year
3.28B
from 3.07B
Increased by 6.67%
EPS This Year
0.82
from -0.38
EPS Next Year
0.96
from 0.82
Increased by 17.81%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.4B | |
| Avg | 3.1B | 3.3B | |
| Low | 2.9B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.7% | 10.3% | |
| Avg | 10.0% | 6.7% | |
| Low | 5.0% | 1.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.86 | 1.08 | |
| Avg | 0.82 | 0.96 | |
| Low | 0.76 | 0.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 32.5% | |
| Avg | - | 17.8% | |
| Low | - | 6.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.